Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter November 28, 2005

Glycogen phosphorylase BB in acute coronary syndromes

Dirk Peetz, Felix Post, Helmut Schinzel, Rosemarie Schweigert, Caroline Schollmayer, Katrin Steinbach, Francesco Dati, Franz Noll and Karl J. Lackner

Abstract

The diagnosis of myocardial damage is preferably based on measurement of the cardiac-specific troponins. However, there is an emerging need for early, specific cardiac markers. One potential candidate is the glycogen phosphorylase BB isoenzyme (GPBB). We investigated the use of a new, commercially available GPBB ELISA assay in 61 patients presenting with an acute coronary syndrome (37 acute myocardial infarction, 24 unstable angina pectoris) in comparison to established cardiac markers such as troponin T, creatine kinase isoenzyme MB (CKMB) mass, and myoglobin. Blood samples were obtained on arrival, as well as 1, 2, 3, 4, 8, 12 and 24h later. GPBB plasma concentrations were elevated in 90.9% of patients 1h after onset of chest pain and increased to 100% at 4–5h. Within the first 6h, GPBB showed the highest sensitivity (95.5–100%) and high specificity (94–96%) compared to myoglobin (85–95% sensitivity) and CKMB mass (71.4–91.3% sensitivity). As expected, troponin T showed high specificity (100%) and sensitivity >95% later in the time course (≥3h). In un-stable angina pectoris patients, a very high rate of elevated GPBB was observed (93.9% at 3h) compared to myoglobin (66.7%). Cardiac troponin T and CKMB were only elevated in 33.8% and 55.0% of these patients, respectively. In conclusion, GPBB is a promising marker for the early diagnosis of acute coronary syndromes and could probably act as a marker of ischemia. However, further studies on specificity and development of a fast, automated assay are necessary before GPBB can be recommended as a routine diagnostic tool.


Corresponding author: PD Dr. Dirk Peetz, Institute of Clinical Chemistry and Laboratory Medicine, Johannes Gutenberg-University, Langenbeckstraße 1, 55101 Mainz, Germany Phone: +49-6131-172632, Fax: +49-6131-176627,

References

1. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined – a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36:959–69.Search in Google Scholar

2. Christenson RH, Duh SH, Sanhai WR, Wu AH, Holtman V, Painter P, et al. Characteristics of an Albumin Cobalt Binding test for assessment of acute coronary syndrome patients: a multicenter study. Clin Chem 2001; 47:464–70.Search in Google Scholar

3. Alhadi HA, Fox KA. Do we need additional markers of myocyte necrosis: the potential value of heart fatty-acid-binding protein. QJM 2004; 97:187–98.Search in Google Scholar

4. Rabitzsch G, Mair J, Lechleitner P, Noll F, Hofmann U, Krause EG, et al. Immunoenzymometric assay of human glycogen phosphorylase isoenzyme BB in diagnosis of ischemic myocardial injury. Clin Chem 1995; 41:966–78.Search in Google Scholar

5. Entman ML, Bornet EP, Van Winkle WB, Goldstein MA, Schwartz A. Association of glycogenolysis with cardiac sarcoplasmic reticulum: II. Effect of glycogen depletion, deoxycholate solubilization and cardiac ischemia: evidence for a phorphorylase kinase membrane complex. J Mol Cell Cardiol 1977; 9:515–28.Search in Google Scholar

6. Newgard CB, Hwang PK, Fletterick RJ. The family of glycogen phosphorylases: structure and function. Crit Rev Biochem Mol Biol 1989; 24:69–99.Search in Google Scholar

7. Kato K, Shimizu A, Kurobe N, Takashi M, Koshikawa T. Human brain-type glycogen phosphorylase: quantitative localization in human tissues determined with an immunoassay system. J Neurochem 1989; 52:1425–32.Search in Google Scholar

8. Krause EG, Rabitzsch G, Noll F, Mair J, Puschendorf B. Glycogen phosphorylase isoenzyme BB in diagnosis of myocardial ischaemic injury and infarction. Mol Cell Biochem 1996; 160/161:289–95.Search in Google Scholar

9. Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003; 24:28–66.Search in Google Scholar

10. Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CW, McFadden E, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002; 23:1809–40.Search in Google Scholar

11. Panteghini M. Acute coronary syndrome: biochemical strategies in the troponin era. Chest 2002; 122:1428–35.Search in Google Scholar

12. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial in-farction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). http://www.acc.org/clinical/guidelines/unstable/unstable.pdf.Search in Google Scholar

13. Jesse RL. Rationale for the early clinical application of markers of ischemia in patients with suspected acute coronary syndromes. In: Wu AH, editor. Cardiac markers, 2nd ed. Totowa, NJ: Humana Press, 2003:245–57.Search in Google Scholar

14. Morrow DA, de Lemos JA, Sabatine MS, Antman EM. The search for a biomarker of cardiac ischemia. Clin Chem 2003; 49:537–9.Search in Google Scholar

15. Wu AH, Morris DL, Fletcher DR, Apple FS, Christenson RH, Painter PC. Analysis of the Albumin Cobalt Binding (ACB) test as an adjunct to cardiac troponin I for the early detection of acute myocardial infarction. Cardiovasc Toxicol 2001; 1:147–51.Search in Google Scholar

16. Peeters RA, in't Groen MA, Veerkamp JH. The fatty acid-binding protein from human skeletal muscle. Arch Biochem Biophys 1989; 274:556–63.Search in Google Scholar

17. Sorichter S, Mair J, Koller A, Pelsers MM, Puschendorf B, Glatz JF. Early assessment of exercise induced skeletal muscle injury using plasma fatty acid binding protein. Br J Sports Med 1998; 32:121–4.Search in Google Scholar

18. Apple FS, Wu AH, Mair J, Ravkilde J, Panteghini M, Tate J, et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 2005; 51:810–24.Search in Google Scholar

19. Rabitzsch G, Mair J, Lechleitner P, Noll F, Hofmann V, Krause EG, et al. Isoenzyme BB of glycogen phosphorylase b and myocardial infarction. Lancet 1993; 341:1032–3.Search in Google Scholar

20. Setsuta K, Seino Y, Takahashi N, Ogawa T, Sasaki K, Harada A, et al. Clinical significance of elevated levels of cardiac troponin T in patients with chronic heart failure. Am J Cardiol 1999; 84:608–11.Search in Google Scholar

21. Peetz D, Schutt S, Sucke B, Faldum A, Wandel E, Hafner G, et al. Prognostic value of troponin T, troponin I, and CK-MB mass in patients with chronic renal failure. Med Klin (Munich) 2003; 98:188–92.Search in Google Scholar

22. Byrick RJ. Fat embolism and postoperative coagulopathy. Can J Anaesth 2001; 48:618–21.Search in Google Scholar

23. Backlund M, Lepantalo M, Toivonen L, Tuominen M, Tarkkil P, Pere P, et al. Factors associated with post-operative myocardial ischaemia in elderly patients undergoing major non-cardiac surgery. Eur J Anaesthesiol 1999; 16:826–33.Search in Google Scholar

24. Richter F, Bohme HJ, Hofmann E. Changes of glycogen phosphorylase isozyme pattern, in rat tissues during pre- and postnatal development. Biomed Biochim Acta 1988; 47:743–52.Search in Google Scholar

25. Mair J. Glycogen phosphorylase isoenzyme BB to diagnose ischaemic myocardial damage. Clin Chim Acta 1998; 272:79–86.Search in Google Scholar

Received: 2005-8-1
Accepted: 2005-9-27
Published Online: 2005-11-28
Published in Print: 2005-12-1

©2005 by Walter de Gruyter Berlin New York